Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Celebrating its 40th anniversary in 2021, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new tools and technologies, investment growth, and career opportunities. Through its cornerstone Magazine, dynamic Website, high-frequency eNewsletters, and innovative suite of multimedia, GEN is the 360-degree resource that researchers and executives depend on for information that is pivotal for their success.
GEN’s breadth of editorial coverage is unrivaled, providing exclusive reporting, insight, and analysis across the life sciences – from its five foundational pillars of Drug Discovery, Bioprocessing, OMICS, Translational Medicine, and Gene Editing to a new, expanded focus on the emerging areas of Cancer Research, Infectious Diseases, and Artificial Intelligence.
Within these areas, GEN delivers exclusive, high-quality reporting on the latest industry news; insider information on cutting-edge tools and technologies; industry-standard protocols, tutorials, and technical articles; first-looks at emerging industry collaborations and investments; reports from key scientific and industry meetings; and A-Lists, our monthly insight and analysis into the top companies, products, and movers & shakers impacting the industry today.
|
|
|
51-200 employees
View all Genetic Engineering & Biotechnology News employees
|
|
Publishing
|
|
140 Huguenot St, New Rochelle, New York 10801, US
|
|
1981
|
|
Biotechnology, Drug Discovery, Translational Medicine, Bioprocessing, Genome Editing, Omics
|
The decision makers in Genetic Engineering & Biotechnology News are James Lambo, John Gilbert, Kevin Davies, etc. Click to Find Genetic Engineering & Biotechnology News decision makers emails.
GEN covers a wide range of topics within the biotechnology and pharmaceutical industries. Key areas include drug discovery, translational medicine, bioprocessing, genome editing, and OMICS technologies. The publication provides in-depth articles, news updates, and expert opinions on the latest advancements, trends, and challenges in these fields.
Articles and resources from GEN can be accessed through their official website at http://www.genengnews.com. While some content is available for free, a subscription may be required for full access to premium articles, reports, and special features. Subscriptions can be purchased directly through the website.
Yes, GEN provides a variety of resources for professionals in the biotech industry, including webinars, white papers, and industry reports. These resources are designed to keep professionals informed about the latest research, technologies, and regulatory developments. Additionally, GEN hosts events and conferences that facilitate networking and knowledge sharing among industry experts.
GEN welcomes submissions from researchers, industry professionals, and thought leaders. If you have an article, research paper, or opinion piece that you would like to submit for consideration, you can find the submission guidelines on their website. It is important to follow these guidelines to ensure your submission meets the publication's standards.
GEN primarily serves the biotechnology and pharmaceutical industries. This includes sectors involved in drug discovery, development, and manufacturing, as well as those focused on genetic engineering, genomics, and personalized medicine. The publication aims to provide valuable insights and information that support innovation and advancement within these industries.
To stay updated on the latest news and developments from GEN, you can subscribe to their newsletter, which delivers curated content directly to your inbox. Additionally, you can follow GEN on social media platforms such as Twitter, LinkedIn, and Facebook for real-time updates and insights. Regularly visiting their website will also keep you informed about new articles and features.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.